What is the expected therapeutic outcome of the simultaneous administration of two medications?

Polypharmacy is defined as the use of multiple medications by a patient, with 5–10 medications usually accepted as the cutoff.

From: Geriatric Rehabilitation, 2018

  1. Cereghino JJ, Brock J, Meter JCV, Pentry JK, Smith LD, White BG. Carbamazepine for epilepsy. Neurology. 1974;24(5):401.

    Article  CAS  PubMed  Google Scholar 

  2. Smith TW, Haber E. Digoxin intoxication: the relationship of clinical presentation to serum digoxin concentration. J Clin Invest. 1970, Dec;49(12):2377–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Buchthal F, Svensmark OLE, Schiller PJ. Clinical and electroencephalographic correlations with serum levels of diphenylhydantoin. A.M.a. Arch Neurol. 1960;2(6):624–30.

    Article  CAS  PubMed  Google Scholar 

  4. Bialer M, Levy RH, Perucca E. Does carbamazepine have a narrow therapeutic plasma concentration range? Ther Drug Monit. 1998, Feb;20(1):56–9.

    Article  CAS  PubMed  Google Scholar 

  5. Centre For Reviews and Dissemination. Systematic reviews : CRD's guidance for undertaking reviews in health care. York: University of York; 2009.

    Google Scholar 

  6. Higgins JPT, Green S, Collaboration C. Cochrane handbook for systematic reviews of interventions. Chichester, England. Hoboken: Wiley; 2008.

    Book  Google Scholar 

  7. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC med res Methodol. 2007, Feb;7(1):10.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Cooney L, Hawcutt D, Sinha I. The evidence for intravenous theophylline levels between 10-20mg/L in children suffering an acute exacerbation of asthma: a systematic review. PLoS One. 2016;11(4):e0153877.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Konidari A, Anagnostopoulos A, Bonnett LJ, Pirmohamed M, El-Matary W. Thiopurine monitoring in children with inflammatory bowel disease: a systematic review. Br J Clin Pharmacol. 2014;78(3):467–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Sparshatt A, Taylor D, Patel MX, Kapur S. Amisulpride - dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring. Acta Psychiatr Scand. 2009;120(6):416–28.

    Article  CAS  PubMed  Google Scholar 

  11. Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation. 2008;85(12):1675–85.

    Article  CAS  PubMed  Google Scholar 

  12. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology. 2006, Apr;130(4):1047–53.

    Article  CAS  PubMed  Google Scholar 

  13. Prybylski JP. Vancomycin trough concentration as a predictor of clinical outcomes in patients with Staphylococcus aureus bacteremia: a meta-analysis of observational studies. Pharmacotherapy. 2015;35(10):889–98.

    Article  CAS  PubMed  Google Scholar 

  14. Sparshatt A, Taylor D, Patel MX, Kapur S. A systematic review of aripiprazole—dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry. 2010;71(11):1447–56.

    Article  CAS  PubMed  Google Scholar 

  15. Zuk DM, Pearson GJ. Monitoring of mycophenolate mofetil in orthotopic heart transplant recipients—a systematic review. Transplant rev. 2009;23:171–7.

    Article  Google Scholar 

  16. Bishara D, Olofinjana O, Sparshatt A, Kapur S, Taylor D, Patel M. Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response. J Clin Psychopharmacol. 2013;33:329–35.

    Article  CAS  PubMed  Google Scholar 

  17. Moreau AC, Paul S, Del Tedesco E, Rinaudo-Gaujous M, Boukhadra N, Genin C, et al. Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory disease: a meta-analysis. Inflamm Bowel Dis. 2014, Mar;20(3):464–71.

    Article  PubMed  Google Scholar 

  18. Cucherat M. Méta-analyse des essais thérapeutiques. France: Masson; 1997.

    Google Scholar 

  19. Kullar R, Leonard SN, Davis SL, Delgado G, Pogue JM, Wahby KA, et al. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg/L suggested by the vancomycin consensus guidelines. Pharmacotherapy. 2011;31(5):441–8.

    Article  CAS  PubMed  Google Scholar 

  20. Rylance GW, Moreland TA. Drug level monitoring in paediatric practice. Arch Dis Child. 1980;55(2):89–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Turner-Warwick M. Study of theophylline plasma levels after oral administration of new theophylline compounds. Br med J. 1957, Jul 13;2(5036):67–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, et al. Developing core outcome sets for clinical trials: issues to consider. Trials. 2012;13(1):132.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Core outcome measures in effectiveness trials (COMET) initiative; Available from: http://www.comet-initiative.org. Accessed 7 January 2017.

  24. Boers M, Idzerda L, Kirwan JR, Beaton D, Escorpizo R, Boonen A, et al. Toward a generalized framework of core measurement areas in clinical trials: a position paper for OMERACT 11. J Rheumatol. 2014;41(5):978–85.

    Article  PubMed  Google Scholar 

  25. Sinha IP, Gallagher R, Williamson PR, Smyth RL. Development of a core outcome set for clinical trials in childhood asthma: a survey of clinicians, parents, and young people. Trials. 2012;13(1):103.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Loke YK, Price D, Herxheimer A. Systematic reviews of adverse effects: framework for a structured approach. BMC med res Methodol. 2007, Jul;7(1):1.

    Article  Google Scholar 

  27. Doyle LW, Halliday HL, Ehrenkranz RA, Davis PG, Sinclair JC. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics. 2005;115(3):655–61.

    Article  PubMed  Google Scholar 

  28. Murphy BP, Inder TE, Huppi PS, Warfield S, Zientara GP, Kikinis R, et al. Impaired cerebral cortical gray matter growth after treatment with dexamethasone for neonatal chronic lung disease. Pediatrics. 2001;107(2):217–21.

    Article  CAS  PubMed  Google Scholar 

  29. Shinwell ES, Karplus M, Reich D, Weintraub Z, Blazer S, Bader D, et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed. 2000;83(3):F177–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Antonucci R, Zaffanello M, Puxeddu E, Porcella A, Cuzzolin L, Dolores Pilloni M, et al. Use of non-steroidal anti-inflammatory drugs in pregnancy: impact on the fetus and newborn. Curr Drug Metab. 2012;13(4):474–90.

    Article  CAS  PubMed  Google Scholar 

  31. Gelenberg AJ, Kane JM, Keller MB, Lavori P, Rosenbaum JF, Cole K, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J med. 1989;321(22):1489–93.

    Article  CAS  PubMed  Google Scholar 

  32. Greeff O, Van Tonder J, Cromarty D, Lowman W, Becker P, Nell M. A multi-centre, phase IV study to evaluate the steady-state plasma concentration and serum bactericidal activity of a generic teicoplanin preparation. South Afr J Infect Dis. 2015;30(3):89–94.

    Google Scholar 

  33. Katrak P, Bialocerkowski AE, Massy-Westropp N, Kumar S, Grimmer KA. A systematic review of the content of critical appraisal tools. BMC med res Methodol. 2004;4:22.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. Bmj. 2016;355:i4919.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ: British Medical Journal. 2011, Oct;343:d5928.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Critical appraisal skills programme. 12 questions to help you make sense of cohort study; Available from: http://media.wix.com/ugd/dded87_e37a4ab637fe46a0869f9f977dacf134.pdf. Accessed 11 January 2017.

  37. National institute of clinical excellence defined criteria for quality assessment of case series; Available from: https://www.nice.org.uk/guidance/cg3/resources/appendix-4-quality-of-case-series-form2. Accessed 11 January 2017.


Page 2

Author Drug Indication Protocol Number of studies Adverse effects Study design “drug monitoring” included in search Information sources RoB/Quality assessment of studies Meta analysis
Cooney 2016 [8] Aminophylline Asthma No 12 Yes No restrictions No Medine, CINAHL, Cochrane Central, and Web of Science Cochrane tool for assessment of risk of bias [35], CASP tool [36] No
Sparshatt 2009 [10] Amisulpride Schizophrenia/schizoaffective disorder No 10 Yes No restrictions No Embase, Medline and PubMed None No
Sparshatt 2010 [14] Aripirazole No specific diagnosis No 8 No No restrictions Yes Embase, Medline, and PubMed None No
Knight 2008 [11] Mycophenolate Mofetil Transplant patients No 12 Yes RCTs, Observational studies No Medline, Embase, Cochrane Central, Transplant Library, Clinical trial registries None No
Zuk 2009 [15] Mycophenolate Mofetil Heart transplant No 7 No No restrictions Yes Medline Embase None No
Bishara 2013 [16] Olanzapine Schizophrenia/schizoaffective disorder/bipolar disorder No 30 Yes No restrictions Yes PubMed, Medline, Embase None Yes
Konidari 2014 [9] Thiopurine IBD No 15 Yes RCTs, Observational studies Yes PubMed, Medline, UK national health system database NICE defined criteria for quality assessment of case series [37] No
Moreau 2014 [17] Thiopurine IBD Yes 17 No No restrictions Yes Medline, Cochrane Library, DirectScience, and Google Scholar Nonea Yes
Osterman 2006 [12] Thiopurine IBD No 12 No No restrictions No Medline, PubMed Plus None Yes
Prybylski 2015 [13] Vancomycin S. aureus bacteraemia No 14 No Observational studies No PubMed None Yes

  1. RoB Risk Of bias, IBD Inflammatory Bowel Disease, RCT Randomised controlled trial, CENTRAL Central Register of Controlled Trials
  2. aMoreau et al. used the MOOSE consensus statement to assess reporting quality, but do not report the results of their assessment